FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569920121> ?p ?o ?g. }

• W2569920121 abstract "Abstract Abstract 878 Background PTLD is a rare disorder affecting 1 to 10% of transplant recipients. Data from prospective trials is scarce. For more than 30 years, reduction of immunosuppression has been the basis of treatment despite generally low efficacy. The introduction of rituximab monotherapy has significantly improved remission rates in CD20-positive B-cell PTLD, but long-term disease control remains problematic. CHOP chemotherapy can achieve this goal, but is associated with a high lethal toxicity of 20% to 30%. Thus, we initiated an international multicenter phase II trial to investigate whether the subsequent application of 4 courses of rituximab and 4 cycles of CHOP-21 would improve the outcome. Methods Treatment-naive adult solid organ transplant recipients diagnosed with CD20-positive PTLD received 4 courses of rituximab (375 mg/m2) once a week followed by 4 weeks without treatment and 4 cycles of 3-weekly CHOP. In case of disease progression during rituximab monotherapy, CHOP was commenced immediately. Supportive therapy with G-CSF was mandatory and antibiotic prophylaxis was recommended. The primary endpoint was response and duration of response. Secondary endpoints were treatment toxicity and overall survival. Analysis was by intention to treat. This study is registered with EudraCT number 2005-000743-29. Results 74 patients were enrolled between Jan. 2003 and Dec. 2007. 70 were allocated to treatment (4 excluded due to missing or withdrawn informed consent). Median age at diagnosis of PTLD was 53.3 years (range 16–74 years). The transplanted organs were kidney (29/70), liver (16/70), heart (14/70), lung (4/70), heart + lung (2/70), kidney + pancreas (4/70) and bone marrow (1/70, protocol violation). Median time of follow up was 5.1 years. PTLD occurred late (more than one year after transplantation) in 76%, with disseminated disease (Ann Arbor stage >II) in 74%. Histology was monomorphic in 84% and EBV-association was present in 44%. Patients with EBV-associated PTLD had a significantly different pattern of involvement and a significantly worse performance status. 66/70 patients (94%) received chemotherapy: two had died prior to CHOP and two were considered not eligible. Chemotherapy-induced grade 3/4 leukocytopenia occurred in 68% and grade 3/4 infections in 41% of patients. The planned dose of CHOP was reduced by more than 25% in 14% of patients. Dose reductions were significantly more frequent in EBV-associated PTLD and did correlate with more frequent grade 3/4 infections. Treatment-associated mortality of CHOP was 10.6% (7/66), the majority of which affected rituximab non-responders (5/7). The overall response rate was 90% (67% complete response, see figure 1). Median duration of remission for treatment responders is not yet reached and 74% are progression free at 3 and 5-years (figure 1A). Median overall survival was 6.6 years (figure 2B). EBV-association predicted time to progression (TTP) in adjusted Cox regression analysis (HR: 0.150, p=0.027), but patients with EBV- and non-EBV-associated PTLD demonstrated similar TTP intervals by univariate analysis. Notably, response to rituximab at interim staging predicted TTP (p=0.028) and OS (p=0.014), which was the reason to cease accrual to the protocol in 2007 and introduce risk-stratified sequential treatment (RSST). Discussion This is the largest prospective trial in the field of PTLD published so far. Sequential treatment with rituximab and CHOP results in excellent disease control and overall survival in adults with PTLD, adding more than three years of life in comparison to historical results achieved with 1st-line rituximab monotherapy and 2nd-line (chemo)-therapy. TRM after sequential treatment is lower than historically reported for CHOP 1st-line therapy. The lower TRM from CHOP in rituximab responders versus non-responders supports the idea that it is a function of tumor burden. In conclusion, sequential treatment with 4 courses of rituximab followed by 4 cycles of three-weekly CHOP + GCSF provides an excellent standard of care for patients with both EBV-associated and non-EBV-associated B-cell PTLD failing to experience sustained response to upfront reduction of immunosuppression. Disclosures: Trappe: AMGEN: Research Funding; Mundipharma: Research Funding; CSL Behring: Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding. Oertel:Roche: Employment, Equity Ownership. Leblond:Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees. Salles:Roche and/or Genetech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genzyme: Membership on an entity's Board of Directors or advisory committees; Calistoga/Gilead: Membership on an entity's Board of Directors or advisory committees. Morschhauser:Roche/Genetech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Choquet:Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2569920121 created "2017-01-13" @default.
• W2569920121 creator A5001784294 @default.
• W2569920121 creator A5014153145 @default.
• W2569920121 creator A5015917994 @default.
• W2569920121 creator A5026409990 @default.
• W2569920121 creator A5026625329 @default.
• W2569920121 creator A5028727344 @default.
• W2569920121 creator A5037133740 @default.
• W2569920121 creator A5045374333 @default.
• W2569920121 creator A5046343753 @default.
• W2569920121 creator A5047962328 @default.
• W2569920121 creator A5051605599 @default.
• W2569920121 creator A5055652911 @default.
• W2569920121 creator A5061694042 @default.
• W2569920121 creator A5066826766 @default.
• W2569920121 creator A5080115270 @default.
• W2569920121 creator A5084858618 @default.
• W2569920121 creator A5086354986 @default.
• W2569920121 creator A5091740511 @default.
• W2569920121 date "2011-11-18" @default.
• W2569920121 modified "2023-09-30" @default.
• W2569920121 title "Sequential Treatment with Rituximab Followed by CHOP Chemotherapy in Adult B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) - Establishing a New Standard of Care: Final Results From the Prospective International Multicenter PTLD-1 Trial" @default.
• W2569920121 doi "https://doi.org/10.1182/blood.v118.21.878.878" @default.
• W2569920121 hasPublicationYear "2011" @default.
• W2569920121 type Work @default.
• W2569920121 sameAs 2569920121 @default.
• W2569920121 citedByCount "0" @default.
• W2569920121 crossrefType "journal-article" @default.
• W2569920121 hasAuthorship W2569920121A5001784294 @default.
• W2569920121 hasAuthorship W2569920121A5014153145 @default.
• W2569920121 hasAuthorship W2569920121A5015917994 @default.
• W2569920121 hasAuthorship W2569920121A5026409990 @default.
• W2569920121 hasAuthorship W2569920121A5026625329 @default.
• W2569920121 hasAuthorship W2569920121A5028727344 @default.
• W2569920121 hasAuthorship W2569920121A5037133740 @default.
• W2569920121 hasAuthorship W2569920121A5045374333 @default.
• W2569920121 hasAuthorship W2569920121A5046343753 @default.
• W2569920121 hasAuthorship W2569920121A5047962328 @default.
• W2569920121 hasAuthorship W2569920121A5051605599 @default.
• W2569920121 hasAuthorship W2569920121A5055652911 @default.
• W2569920121 hasAuthorship W2569920121A5061694042 @default.
• W2569920121 hasAuthorship W2569920121A5066826766 @default.
• W2569920121 hasAuthorship W2569920121A5080115270 @default.
• W2569920121 hasAuthorship W2569920121A5084858618 @default.
• W2569920121 hasAuthorship W2569920121A5086354986 @default.
• W2569920121 hasAuthorship W2569920121A5091740511 @default.
• W2569920121 hasConcept C126322002 @default.
• W2569920121 hasConcept C141071460 @default.
• W2569920121 hasConcept C168563851 @default.
• W2569920121 hasConcept C203092338 @default.
• W2569920121 hasConcept C2775965419 @default.
• W2569920121 hasConcept C2776694085 @default.
• W2569920121 hasConcept C2779338263 @default.
• W2569920121 hasConcept C2779725641 @default.
• W2569920121 hasConcept C2780252810 @default.
• W2569920121 hasConcept C2780653079 @default.
• W2569920121 hasConcept C2781146716 @default.
• W2569920121 hasConcept C2911091166 @default.
• W2569920121 hasConcept C2992435398 @default.
• W2569920121 hasConcept C535046627 @default.
• W2569920121 hasConcept C71924100 @default.
• W2569920121 hasConceptScore W2569920121C126322002 @default.
• W2569920121 hasConceptScore W2569920121C141071460 @default.
• W2569920121 hasConceptScore W2569920121C168563851 @default.
• W2569920121 hasConceptScore W2569920121C203092338 @default.
• W2569920121 hasConceptScore W2569920121C2775965419 @default.
• W2569920121 hasConceptScore W2569920121C2776694085 @default.
• W2569920121 hasConceptScore W2569920121C2779338263 @default.
• W2569920121 hasConceptScore W2569920121C2779725641 @default.
• W2569920121 hasConceptScore W2569920121C2780252810 @default.
• W2569920121 hasConceptScore W2569920121C2780653079 @default.
• W2569920121 hasConceptScore W2569920121C2781146716 @default.
• W2569920121 hasConceptScore W2569920121C2911091166 @default.
• W2569920121 hasConceptScore W2569920121C2992435398 @default.
• W2569920121 hasConceptScore W2569920121C535046627 @default.
• W2569920121 hasConceptScore W2569920121C71924100 @default.
• W2569920121 hasLocation W25699201211 @default.
• W2569920121 hasOpenAccess W2569920121 @default.
• W2569920121 hasPrimaryLocation W25699201211 @default.
• W2569920121 hasRelatedWork W2286803867 @default.
• W2569920121 hasRelatedWork W2550331610 @default.
• W2569920121 hasRelatedWork W2551961320 @default.
• W2569920121 hasRelatedWork W2553921380 @default.
• W2569920121 hasRelatedWork W2557565072 @default.
• W2569920121 hasRelatedWork W2560706872 @default.
• W2569920121 hasRelatedWork W2576187300 @default.
• W2569920121 hasRelatedWork W2578876390 @default.
• W2569920121 hasRelatedWork W2594555211 @default.
• W2569920121 hasRelatedWork W2619256369 @default.
• W2569920121 hasRelatedWork W2625284726 @default.
• W2569920121 hasRelatedWork W2793918023 @default.
• W2569920121 hasRelatedWork W2910217857 @default.
• W2569920121 hasRelatedWork W2914872421 @default.
• W2569920121 hasRelatedWork W2979931387 @default.
• W2569920121 hasRelatedWork W2980608967 @default.
• W2569920121 hasRelatedWork W2984974494 @default.
• W2569920121 hasRelatedWork W2986728179 @default.
• W2569920121 hasRelatedWork W2991519754 @default.
• W2569920121 hasRelatedWork W61585537 @default.

• next